{'fraction_non_alphanumeric': 0.023359840954274354, 'fraction_numerical': 0.01242544731610338, 'mean_word_length': 5.535714285714286, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Differential sensitivities of long-term cultured cell lines derived from human haematopoietic malignancies to various anti-cancer drugs.

transplanted at relapse has survived more than 1 yr after transplantation while 4 of ll (36%) transplanted in remission have survived. As for GVHD, 1 yr survival rates were 50% (2/4) and 14% (2/14) in patients with and without acute GVHD respectively; they were 50% (1/2) and 75% (3/4) in patients with and without chronic GVHDrespectively. These observations clearly demonstrate that allogeneic bone marrow transplantation can produce relatively high long-term survival rates in the treatment of acute leukemia. One patient is now surviving in unmaintained remission almost 6 yr after transplantation. In this patient, acute leukemia is probably cured. Another patient with T cell-ALL was transplanted during first remission because poor prognosis was expected. The patient has survived more than 3 yr after transplantation. Patients with ALL are usually transplanted during second or later remission because the disease is curable in a considerable portion of the patients by conventional chemotherapy. Since posttransplant relapse rates have been high in patients with ALL, bone marrow transplantation during first remission will be an effective approach in the treatment of high risk ALLwith poor prognosis. When results were analysed in relation with posttransplant survival, younger age of the recipients, transplantation during remission and the presence of acute GVHD are factors which favorably influence 1 yr survival after transplantation. Therefore, long-term survival will be highly expected in younger patients with acute leukemia when bone marrowtransplantation is performed during complete remission. Furthermore, transplantation during remission will have advantages in reducing major or fatal complications compared with that at relapse. Among transplantationrelated complications, interstitial pneumonia is one of the most important problems to be solved.